Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Regulatory News (CSRT)

  • There is currently no data for CSRT

King Systems - New Digital Technology

18 Oct 2010 07:00

RNS Number : 5329U
Consort Medical PLC
18 October 2010
 



 

 

News Release

 

18 October 2010

 

 

Consort Medical plc

 

King Systems Brings New Digital Technology to Anaesthesia

Consort Medical is pleased to announce the launch by its King Systems Division of its King VisionTM Video Laryngoscope, the world's first cost-effective, portable video laryngoscope.

Last year over 40 million anaesthesia procedures were performed worldwide using a plastic endotracheal tube to help patients breathe during surgery. This procedure, typically performed by an anaesthetist to protect the airway, takes just a few moments but requires the use of a metal lever-like device called a laryngoscope to provide a clear pathway for the tube. The anaesthetist must manipulate the soft tissues to directly see the vocal cords, which is not always possible with all patients.

King Systems' innovative solution, the King Vision Video Laryngoscope, incorporates a camera in the tip of the disposable device and an attached reusable video display which allows the clinician a clear view of the vocal cords without manipulating and potentially damaging soft tissue, easing the process and simplifying the procedure.

 

The King Vision has been launched and orders are being taken. Shipments are expected to begin by the end of the financial year as the manufacturing supply chain ramps up its capacity. Further information will be provided at Consort Medical's interim results on 2 December 2010.

 "Direct laryngoscopy has been effective and inexpensive for over 75 years; however, the view is often compromised, the manoeuvre is physical, and the placement must be directly observed by the clinician. The King Vision is a new digital technology that will revolutionize the way intubations are performed around the world. We are extremely proud to be able to bring this potentially life saving device into the realm of every day routine intubations," said Don Dumoulin, CEO of King Systems.

King Systems, a Consort Medical company, is a global leader in medical device manufacturing providing high-quality, innovative products. King Systems delivers life saving solutions to enhance better patient care.

ENDS

 

 

 

For enquiries, please contact:

 

Consort Medical plc

Jonathan Glenn, Chief Executive

Tel: +44 (0) 1442 867920

Toby Woolrych, Group Finance Director

Tel: +44 (0) 1442 867920

Brunswick

Jon Coles/Justine McIlroy

Tel: +44 (0) 20 7404 5959

 

 

About King Systems

 

King Systems is the US market leader in the sale of circuits and masks to anaesthesiologists and has a growing presence in the airway management segment with the King Laryngeal Tube (KLT) range. Further details can be seen on www.kingsystems.com and www.owntheairway.com

 

About Consort Medical

 

Consort Medical plc is a leader in medical devices for inhaled drug delivery, self-injection and anaesthesia. The Group develops drug delivery systems for the pharmaceutical industry and disposable airway management products for critical care settings in hospitals.

 

Consort Medical develops and manufactures metered dose inhaler valves, actuators, compliance aids, dry powder devices autoinjectors, disposable facemasks, breathing circuits and laryngeal tubes. The Group has facilities in King's Lynn, Sheffield, Nelson and Hemel Hempstead in the UK, and Indianapolis, Indiana and Kent, Ohio in the US. Consort Medical is a public company quoted on the full list of the London Stock Exchange (LSE: CSRT).

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGUBDGXSBBGGI
Date   Source Headline
15th Jun 20123:12 pmRNSDirector/PDMR Shareholding
14th Jun 20127:00 amRNSDirectorate
14th Jun 20127:00 amRNSPreliminary Results
6th Jun 20121:57 pmRNSBlocklisting Interim Review
1st May 201210:21 amRNSTotal Voting Rights
30th Apr 20127:00 amRNSFDA Approval Proprietary Integrated Dose Counter
20th Apr 201210:54 amRNSHolding(s) in Company
16th Apr 201211:37 amRNSBlocklisting Interim Review
28th Mar 20124:36 pmRNSHolding(s) in Company
22nd Mar 20129:58 amRNSAnnual Information Update
20th Mar 20124:25 pmRNSReplacement Interim Management Statement
20th Mar 20121:07 pmRNSInterim Management Statement
1st Mar 20129:00 amRNSTotal Voting Rights
17th Feb 201210:09 amRNSHolding(s) in Company
23rd Jan 20129:45 amRNSBlocklisting Interim Review
13th Dec 20112:25 pmRNSDirector/PDMR Shareholding
2nd Dec 20111:34 pmRNSBlocklisting Interim Review
1st Dec 20117:00 amRNSInterim results for the six months ended 31/10/11
19th Oct 20114:03 pmRNSHolding(s) in Company
17th Oct 20113:13 pmRNSHolding(s) in Company
14th Oct 20119:39 amRNSBlocklisting Interim Review
7th Oct 201112:13 pmRNSHolding(s) in Company
5th Oct 20114:47 pmRNSHolding(s) in Company
4th Oct 20117:00 amRNSSecond Nasal Drug Delivery Contract
27th Sep 20114:33 pmRNSHolding(s) in Company
26th Sep 20113:01 pmRNSHolding(s) in Company
2nd Sep 201110:21 amRNSTotal Voting Rights
1st Sep 20112:50 pmRNSResult of AGM
1st Sep 20112:47 pmRNSDirectorate Change
1st Sep 201112:40 pmRNSInterim Management Statement
1st Sep 20117:00 amRNSNasal Drug Delivery Contract
24th Aug 20114:35 pmRNSHolding(s) in Company
2nd Aug 20111:51 pmRNSDirector/PDMR Shareholding
2nd Aug 20111:47 pmRNSDirector/PDMR Shareholding
28th Jul 20119:14 amRNSAnnual Financial Report
20th Jul 20117:00 amRNSFurther re Investment in Atlas Genetics
30th Jun 20111:58 pmRNSTotal Voting Rights
24th Jun 20119:06 amRNSHolding(s) in Company
21st Jun 201112:33 pmRNSBlocklisting Interim Review
16th Jun 20117:00 amRNSPreliminary results for the year ended 30/04/11
2nd Jun 20117:00 amRNSBlocklisting Interim Review
10th May 20119:27 amRNSHolding(s) in Company
14th Apr 201110:20 amRNSBlocklisting Interim Review
4th Apr 201110:29 amRNSHolding(s) in Company
1st Apr 20111:51 pmRNSHolding(s) in Company
23rd Mar 20112:04 pmRNSAnnual Information Update
14th Mar 20117:00 amRNSInterim Management Statement
15th Feb 20114:14 pmRNSHolding(s) in Company
9th Feb 201111:15 amRNSDirectorate Change
7th Feb 20117:00 amRNSPartners with Atlas Genetics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.